TPP: ‘Missed Opportunity’ Or ‘Unprecedented Assault’?

While there may have been basic consensus on the multi-sector Trans-Pacific Partnership, the final detailed provisions and wording of the massive trade agreement as it pertains to data exclusivity for biologic medicines have yet to be publicly released.

This makes it frustratingly uncertain what exactly has been agreed and with whom, but it does seem clear that a minimum of five years' data exclusivity has been accepted across the board, meaning that such protection is set to apply in some